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Abstract
Background: The Y-box binding protein 1 (YB-1) is considered to be one of the key regulators
of transcription and translation. However, so far only limited knowledge exists regarding its cellular
distribution in the adult brain.
Results: Analysis of YB-1 immunolabelling as well as double-labelling with the neuronal marker
NeuN in rat brain tissue revealed a predominant neuronal expression in the dentate gyrus, the
cornu ammonis pyramidal cell layer, layer III of the piriform cortex as well as throughout all layers
of the parahippocampal cortex. In the hilus of the hippocampus single neurons expressed YB-1. The
neuronal expression pattern was comparable in the hippocampus and parahippocampal cortex of
adult macaques and humans. Double-labelling of YB-1 with the endothelial cell marker Glut-1, the
multidrug transporter P-glycoprotein, and the astrocytic marker GFAP did not indicate a co-
localization. Following status epilepticus in rats, no induction of YB-1 occurred in brain capillary
endothelial cells and neurons.
Conclusion: In conclusion, our study demonstrates that YB-1 is predominantly expressed in
neurons in the adult brain of rats, macaques and humans. Lack of a co-localization with Glut-1 and
P-glycoprotein argues against a direct role of YB-1 in the regulation of blood-brain barrier P-
glycoprotein.
Background
Y-box binding proteins constitute a family of DNA/RNA-
binding proteins that control gene expression at both the
transcriptional and translational level [1,2]. The Y-box
protein 1 (YB-1) represents a major mRNP (ribonucleo-
protein particle) protein modulating the overall structure
of mRNA to regulate translation [3]. With this function,
YB-1 also represents one of the key regulators for expres-
sion of the multidrug transporter P-glycoprotein (Pgp) in
tumor cells [4-10]. Pgp is known to confer cross-resistance
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to a variety of cytotoxic agents, thereby contributing to
tumor resistance and therapeutic failure [11]. Huang et al.
[12] demonstrated a direct link between YB-1 and Pgp
expression in breast cancer cells and suggested YB-1
expression as a marker for chemoresistance, which may
help to guide selection of the chemotherapy regime. Sev-
eral studies confirmed that high YB-1 expression levels are
associated with tumor aggressiveness, failure of chemo-
therapy, and a poor prognosis [13-16].
Over-expression of the multidrug transporter Pgp in
blood-brain barrier (BBB) endothelial cells is discussed as
one putative cause of drug-refractoriness in different CNS
diseases such as epilepsy, depression, schizophrenia, neu-
roAIDS, and brain cancer [17]. Enhanced efflux function
in brain capillary endothelial cells extrudes drugs into the
capillary lumen, thereby reducing drug concentrations at
brain parenchymal targets and contributing to therapeutic
failure. Disease-associated factors as well as drugs are dis-
cussed to affect expression levels of Pgp in CNS diseases
[17]. In view of the suggested role of Pgp in refractoriness,
it is of specific interest to identify the factors which may
contribute to regulation of Pgp in brain capillary endothe-
lial cells. Based on data from tumor cells, we hypothesized
that YB-1 may also co-localize with Pgp in brain capillary
endothelial cells.
Besides induction of Pgp expression, numerous further
changes occur in gene expression in a variety of cell types
following seizure activity in the epileptic brain as well as
during the development of symptomatic epilepsy [18,19].
Whereas some of these changes just reflect consequences
of the insult others may critically contribute to the forma-
tion, stabilization, or extension of a hyperexcitable net-
work. In this context knowledge about the regulators
involved in the complex transcriptome and proteome
changes would increase the understanding of the mecha-
nisms of disease progression and epileptogenesis.
Therefore, it is of specific interest to further elucidate the
role of the transcriptional and translational regulator YB-
1 in the brain. In the present study, we investigated the
cellular localization of YB-1 in brain tissue of rats,
macaques and humans. In view of a putative role of YB-1
in the regulation of Pgp in brain capillaries, we tested if
YB-1 co-localizes with Pgp in brain capillary endothelial
cells. In order to gain knowledge about an impact of YB-1
in the pathophysiology of the diseased brain, the expres-
sion of YB-1 was determined in the early phase following
a status epilepticus.
Methods
Animals and Tissue Information
Female Wistar Unilever rats were purchased at a body
weight of 180–200 g (Harlan-Winkelmann, Borchen, Ger-
many). Rats were kept under controlled environmental
conditions (24–25°C; humidity 50–60%; 12 hour dark/
light cycle) with free access to tap water and food. Before
being used in the experiments, the rats were allowed to
adapt to the new conditions for at least 1 week. All exper-
iments were done in compliance with the European Com-
munities Council Directive of 24 November 1986 (86/
609/EEC). All efforts were made to minimize pain or dis-
comfort of the animals used.
YB-1 expression was studied in the brain of old world pri-
mates and humans. Therefore, brain tissue from a six year
old adult male macaque (Macaca fascicularis), that had
been transcardially perfused with 4% paraformaldehyde
in 0.1 M phosphate buffer was obtained and processed as
described in detail elsewhere [20]. Brain blocks contain-
ing either the hippocampus and parahippocampal cortex
or the parietal cortex were cut in 40 μm sections using a
cryostat (HM 560; Microm, Walldorf, Germany) and were
stored at -20°C in cryoprotecting solution (glycerol and
0.1 M phosphate buffer, pH 7.4, 1:1 in volume). In addi-
tion, 3 μm thin paraffin sections of hippocampus from a
former neuropathological study (for detail see [21]) were
used to evaluate YB-1 expression in the human brain. The
brain tissue of a forty-four year old male subject that
lacked any neuropathological alterations served as a con-
trol in our study.
Induction of Status Epilepticus in rats
For induction of status epilepticus in rats (n = 40) lithium
chloride (127 mg/kg i.p., Sigma, Taufkirchen, Germany)
was administered 14 h and methyl-scopolamine (1 mg/kg
i.p., Sigma; Taufkirchen, Germany) was administered 30
min before the first pilocarpine injection. As described
previously [22] pilocarpine (Sigma, Taufkirchen, Ger-
many) was given intraperitoneally (10 mg/kg) every 30
min until the onset of convulsive status epilepticus (SE)
consisting of ongoing generalized convulsive seizures. The
total number of pilocarpine injections was limited to 12
per animal. Seizure activity was monitored behaviourally.
Status epilepticus was terminated after 90 min by injec-
tion of diazepam (10 mg/kg). If seizure activity contin-
ued, diazepam administration was repeated after 3
minutes. Only rats exhibiting continuous convulsive sei-
zure activity during status epilepticus were used for further
analysis. Control rats (n = 8) were treated similarly, but
saline was given instead of pilocarpine and methyl-scopo-
lamine.
Tissue Preparation
For studying YB-1 expression vehicle treated control rats
(n = 8) and rats with intervals of 2 h (n = 2), 4 h (n = 6),
8 h (n = 7), and 48 h (n = 6) following status epilepticus
were decapitated. The brains were immediately removed,
embedded in Tissue Freezing Medium® (Jung, Nussloch,BMC Neuroscience 2009, 10:28 http://www.biomedcentral.com/1471-2202/10/28
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Germany), frozen in liquid nitrogen and stored at -80°C.
The tissue was cut at 14 μm using a cryostat (HM 560;
Microm, Walldorf, Germany) and sections were mounted
onto HistoBond®  adhesion slides (Marienfeld, Lauda-
Koenigshofen, Germany). For YB-1/NeuN double-label-
ling additional naïve rats were deeply anesthetized with
chloralhydrate and were transcardially perfused with
saline followed by 4% paraformaldehyde in 0.1 M phos-
phate buffered saline (pH 7.4). The brains were removed
and transferred into 30% sucrose and stored at 4°C until
cutting at 40 μm on a cryostat (HM 560; Microm, Wall-
dorf, Germany) in the coronal plane. Sections were stored
at -20°C in cryoprotecting solution (glycerol and 0.1 M
phosphate buffer, pH 7.4, 1:1 in volume).
YB-1 immunostaining
For YB-1 immunohistochemistry frozen sections of rats
were incubated in acetone for 10 minutes at -20°C. Sec-
tions were allowed to air dry at room temperature for two
days, rinsed in 0.05 M Tris-buffered saline (TBS; pH 7.6)
and incubated in 0.5% TBS buffered H2O2 for 30 minutes.
Following a pre-incubation in a blocking solution con-
taining 2% bovine serum albumin, 0.3% Triton X-100,
and 5% normal goat serum (serum was chosen depending
on host species of the secondary antibody) in TBS for 60
minutes, sections were incubated in primary antiserum
containing polyclonal rabbit anti-YB-1 (Abcam, Cam-
bridge, UK) overnight at 4°C. Then, sections were rinsed
in TBS, placed in biotin-labelled goat anti-rabbit (Jackson
Immunoresearch Laboratories, West Grove, PA, USA),
1:200 for 90 minutes, and after rinsing again in TBS sec-
tions were incubated in horseradish peroxidase-labelled
streptavidin (DAKO, Hamburg, Germany), 1:375 for 90
minutes. After several TBS rinses the applied antibodies
were visualized by a nickel-intensified diaminobenzidine
[19] reaction (0.05% 3,3-diaminobenzidine, 0.01%,
nickel ammonium sulphate; both from Sigma,
Taufkirchen, Germany, and 0.01% H2O2). After washing,
the sections were mounted onto glass slides, air dried,
dehydrated, and coverslipped with Entellan (Merck,
Darmstadt, Germany).
For YB-1 immunohistochemistry of the macaque brain
tissue, the same protocol was applied as described for rats
except that the sections were processed free-floating with-
out acetone and drying pre-treatment.
Formalin-fixed, paraffin-embedded brain tissue was first
deparaffinised, rehydrated and pre-treated as described
previously [21,23]. Then, sections were processed as
described for rat and macaque tissue.
For the combined detection of YB-1/Glut-1, sections of
rat, macaque and human brain tissue were preincubated
in donkey serum (Jackson Immunoresearch Laboratories,
West Grove, PA, USA). Then the sections were incubated
in a mixture of polyclonal rabbit anti-YB-1 (Abcam, Cam-
bridge, UK), 1:250 and monoclonal mouse anti-Glut-1
antibody (Abcam, Cambridge, UK), 1:500. After rinsing,
the sections were reacted with a carbocyanin 3-labelled
donkey anti-rabbit (Jackson Immunoresearch Laborato-
ries, West Grove, PA, USA), 1:500, and biotinylated don-
key anti-mouse, 1:500, in combination with carbocyanin
2-conjugated streptavidin, 1:500 (both from Jackson
Immunoresearch Laboratories, West Grove, PA, USA) for
90 min at room temperature.
The simultaneous immunodetection of YB-1 and either
the neuron-specific nuclear antigen (NeuN) or glial fibril-
lary acid protein (GFAP) was performed on free-floating
40 μm thick sections of paraformaldehyde-perfused rats
and macaques. The sections were treated with a mixture of
polyclonal rabbit anti-YB-1 antibody (Abcam Cambridge,
UK) and either monoclonal biotinylated mouse anti-
NeuN antibody or monoclonal mouse anti-GFAP anti-
body (both from Millipore former Chemicon, Hofheim,
Germany) was used. The respective secondary antibodies
anti-rabbit and anti-mouse IgG (Jackson Immunoresearch
Laboratories, West Grove, PA, USA) were used at a dilu-
tion of 1:500.
For combined immunodetection of YB-1 and Pgp frozen
rat brain sections were pretreated as described above for
YB-1 single-labelling, but preincubated in donkey serum
instead of goat serum. Then, sections were incubated in a
mixture of polyclonal rabbit anti-YB-1 (Abcam Cam-
bridge, UK), 1:250 and polyclonal goat anti-Pgp antibody
(Santa Cruz Biotechnology, Heidelberg, Germany), 1:30,
overnight at 4°C. Carbocyanin 3-labelled donkey anti-
rabbit antibody, 1:500, as well as biotinylated donkey
anti-goat antibody, 1:500, in combination with carbocy-
anin 2-conjugated streptavidin, 1:500 (all from Jackson
Immunoresearch Laboratories, West Grove, PA, USA)
were used as secondary antibodies.
Immunohistological evaluation and Statistics
The DAB-stained sections was examined with a Olympus
BH2 microscope with Plan-Neofluar lenses (Zeiss, Göttin-
gen, Germany) equipped with a single chip charge-cou-
pled device (CCD) color camera (Axiocam; Zeiss,
Göttingen, Germany), and connected with an AMD
Athlon64 Processor-based computer with an image cap-
ture interface card (Axiocam MR Interface Rev.A; Zeiss,
Göttingen, Germany). The immunolabelling was ana-
lyzed in different brain regions that are known to be
involved in epileptic circuits, i.e. subregions of the hip-
pocampus, in the parahippocampal cortex, and in rat tis-
sue also in the piriform cortex. Available samples from the
macaque and human brain only included the hippocam-
pus and parahippocampal tissue.BMC Neuroscience 2009, 10:28 http://www.biomedcentral.com/1471-2202/10/28
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For counting of YB-1 positive hilar neurons, the signal of
the immunoperoxidase-treated sections was captured
with the computer-assisted imaging system StereoInvesti-
gator 6.0 (Microbrightfield Europe, Magdeburg, Ger-
many). The hardware consists of a Leica DMLB
microscope (Leica, Bensheim, Germany), a Plan-Neofluar
lens (Leica, Bensheim, Germany), a single chip charge
coupled device (CCD) color camera (CX9000, Micro-
brightfield Europe, Magdeburg, Germany), and an AMD
Athlon (tm) 64 Processor. An experimenter blinded to the
treatment conditions traced the extent of the hippocam-
pal dentate hilus and performed the counting of cells
using the optical fractionator method. In slide-mounted
sections the area of the dentate hilus was traced and
within each traced contour a step grid was placed. Count-
ing frames were automatically and randomly placed along
the grid. The thickness of the counting frame was equal to
the thickness of the section (minus guard zones from the
top and bottom of the section). Only immunoreactive
cells which appeared within the counting frame and came
into focus were counted.
Fluorescent signals from double-labelled sections were
analyzed using a confocal microscope (Leica TCS SP2;
Leica, Bensheim, Germany). For evaluation of double-
labelling or lack of double-labelling confocal z-series of
cells were carefully analyzed.
Statistical differences in cellular counts were analyzed by
one way analysis of variance followed by the Student's t-test
(unpaired). Data are expressed as means ± SEM. A p < 0.05
was considered significant and is indicated by an asterisk.
Results
YB-1 expression in the rat, macaque, and human brain
Analysis of YB-1 immunolabelling in rat brain tissue
revealed a strong expression in the dentate gyrus, the
cornu ammonis pyramidal cell layer, layer III of the piri-
form cortex, as well as throughout all layers of the para-
hippocampal cortex (Fig. 1A–D). Based on the
morphology the vast majority of labelled cells presented a
neuronal phenotype. An identical expression pattern was
observed in the hippocampus and the parahippocampal
cortex of macaques and humans (Fig. 1E–H). In the hilus
of the hippocampus of all three species single YB-1 posi-
tive neurons were evident. Expression of YB-1 in neurons
was substantiated by double-labelling with the neuronal
cell marker NeuN. In rat and macaque tissue representa-
tive YB-1 immunoreactive cells with a neuronal morphol-
ogy were carefully analyzed on serial optical planes. This
analysis confirmed a co-localization of YB-1 and NeuN
(Fig. 2A–B). The majority of cells showed a dominant YB-
1 expression in the cytoplasm, whereas a predominant
nuclear localization of YB-1 was obvious in some cells
only (Fig. 2A–B). In contrast, there was no evidence for a
co-localization of YB-1 with the astroglial cell marker
GFAP in different regions of the rat brain (Fig. 2C).
Thereby these data imply that YB-1 is not expressed in
astrocytes in the naïve brain to a relevant extent.
Furthermore the microscopic analysis of the tissue of all
three species indicated an expression of YB-1 in associa-
tion with brain vessels (Fig. 1A).
Lack of co-localization with the endothelial cell marker 
Glut-1 and with Pgp
In brain tissue of rats, macaques, and humans microves-
sels in all brain regions were intensely stained by Glut-1
immunolabelling. The careful analysis of double Glut-1/
YB-1 immunolabelled sections in serial optical planes did
not reveal any evidence for a YB-1 expression in Glut-1
immunolabelled endothelial cells (Fig. 2D, E).
In all regions of the rat brain tissue, microvessels were
heavily stained by Pgp immunolabelling. On longitudinal
as well as cross-sectioned microvessels, Pgp labelling out-
lined the entire vessel profile, and corresponded to the
endothelial cells at the vessel walls (Fig. 2F). With the
immunohistological procedure used in the present study,
Pgp-specific staining was not observed in neurons or glial
cells. The analysis of serial optical planes of double Pgp/
YB-1 immunolabelled sections did not indicate co-locali-
zation of YB-1 with endothelial Pgp (Fig. 2F).
YB-1 expression following status epilepticus
Seventy-five percent of the rats (n = 30 out of 40) devel-
oped a status epilepticus with generalized convulsive sei-
zures in response to repeated injections of the
cholinomimetic pilocarpine. The rats required a mean
dosage of 32.7 ± 3.59 mg/kg pilocarpine (mean ± SEM) to
develop a status epilepticus. All rats exhibited a compara-
ble ongoing generalized seizure activity continuing until
administration of diazepam.
In brain capillary endothelial cells YB-1 expression was
not induced by status epilepticus. Analysis of Glut-1/YB-1
or Pgp/YB-1 double-labelled sections of representative
samples did not reveal an expression of YB-1 in endothe-
lial cells at different time points following prolonged sei-
zure activity.
The overall expression pattern of YB-1 in hippocampal
cells with a neuronal morphology did not change during
the first 48 h following SE. No induction was observed in
hippocampal cells at the different time points investigated
(Fig. 3). The significant reduction 48 h following SE is
likely to be related to hippocampal cell loss that is known
to be evident at this time point (Fig. 3).
Discussion
YB-1 is a DNA- and RNA-binding protein that functions as
a sequence specific transcriptional and translational regu-BMC Neuroscience 2009, 10:28 http://www.biomedcentral.com/1471-2202/10/28
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Micrographs showing expression of the transcription factor YB-1 in the rat, macaque and human brain (A-H) Figure 1
Micrographs showing expression of the transcription factor YB-1 in the rat, macaque and human brain (A-H). 
(A) Image displaying hippocampal YB-1 expression visualized by a DAB-staining method in a 14 μm thin section of an adult rat's 
hippocampus (DG = dentate gyrus, H = hilus of the dentate gyrus, CA = cornu ammonis formation). (B) Representative exam-
ple of YB-1 expression in the piriform cortex (layer I-III) of an adult rat. Note, that the expression of YB-1 is predominantly 
related to cells in the layer III of the piriform cortex. (C) Image showing YB-1 expressing granule cells of the dentate gyrus and 
YB-1 expressing cells in the hilar (H) subregion of the hippocampus of an adult rat. (D) Image displaying YB-1 expression visu-
alized by a DAB-staining method in a 14 μm thick section of the parahippocampal cortex (PHC) of a rat. YB-1 expression 
appears throughout all layers of the cortex. (E) Image displaying YB-1 expression visualized by a DAB-staining method in a 40 
μm thick section of a macaque's parahippocampal cortex (PHC). In this image YB-1 appears to be stronger expressed as in the 
rat's brain due to the relative thickness of this section in comparison to the thinner sections of the rat. (F) Image displaying YB-
1 expression visualized by a DAB-staining method in a 3 μm thin section of a human parahippocampal cortex (PHC). Due to 
the section thickness of only 3 μm, YB-1 appears to be less expressed compared to images of the rat's and macaque's brain. 
(G) Image displaying YB-1 expressing granule cells of the dentate gyrus (DG) as well as YB-1 expressing cells in the hilar (H) 
subregion and the molecular layer (Mol) of the hippocampal formation in the brain of a macaque. (H) YB-1 expression in the 
hippocampal CA-1 region of the human brain. A: scale bar = 100 μm. B-H: scale bar = 20 μm.BMC Neuroscience 2009, 10:28 http://www.biomedcentral.com/1471-2202/10/28
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lator. Here, we demonstrated that in the adult brain of
rats, macaques, and humans YB-1 is predominantly
expressed in neurons. So far postnatal expression in neu-
rons has only been described in mouse and rat brain
based on Western Blot analysis of brain tissue extracts or
on studies using primary cultures of hippocampal neu-
rons [24,25]. Funakoshi et al. [25] described a decline of
mouse and rat brain expression of YB-1 in the postnatal
phase. Miwa and colleagues [24] reported a hippocampal
expression that was prominent at the age of 5 days but
decreased significantly in 4-week old mice. However, neu-
ronal expression was not confirmed by immunohistolog-
ical double-labelling in these studies and no data were
given about the hippocampal subregions. Our analysis
revealed a prominent expression in granule cells of the
dentate gyrus as well as an expression in the cornu ammo-
nis pyramidal cell layer. Only single cells were labelled in
the hilus of the hippocampus. In comparison to rat and
macaque tissue labelling was less pronounced in human
tissue. This might be related to the processing of the tissue
Micrographs showing multiple-labelled tissue of the rat, macaque and human brain (A-F) Figure 2
Micrographs showing multiple-labelled tissue of the rat, macaque and human brain (A-F). (A) Split image display-
ing labelling of YB-1 (red) and NeuN (green) and double-labelling (merged figure) in the hippocampal cornu ammonis (CA-1) 
formation of a rat brain. Representative examples of cells showing nuclear YB-1 expression are indicated by bold white arrow-
heads while a narrow arrow indicates a cell with cytoplasmatic expression of YB-1. (B) High magnification image of a neuron 
indicated by NeuN expression (green) with a clear nuclear staining of YB-1 (red) in the parietal cortex of a macaque. (C) Split 
image showing the expression of YB-1 (red) and the glial marker GFAP (green) in the hilus of the dentate gyrus of a rat. Note 
the absence of any glial expression of YB-1 in the merged figure. (D, E) Confocal image showing the expression of YB-1 (red) 
and the expression of the endothelial cell marker Glut-1 (green) in the macaque and human brain. (D) Image displaying the 
expression of YB-1 (red) and Glut-1 (green) in the parahippocampal cortex of a macaque monkey. Note the lack of co-localiza-
tion of YB-1 and Glut-1 expression, as clearly indicated by confocal z-series. (E) Image displaying the expression of YB-1 (red) 
and Glut-1 (green) in the human parahippocampal cortex. In accordance with data obtained from rats (data not shown) and 
macaques, YB-1 proved not to be expressed by Glut-1 positive endothelial cells. (F) Split image of a confocal micrograph giving 
an example of YB-1 expression (red) and expression of the endothelial multidrug transporter Pgp (green) in the parietal cortex 
of a rat. In accordance with the data from the YB-1/Glut-1 double-labelling in the different species, YB-1 does not co-localize 
with endothelial Pgp expression (merged figure). Scale bar = 10 μm.BMC Neuroscience 2009, 10:28 http://www.biomedcentral.com/1471-2202/10/28
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or to differences in the affinity of the antibody to the YB-
1 isoforms of the different species. In the parahippocam-
pal cortex of all species YB-1 neuronal expression was evi-
dent with a distribution that appeared to be independent
of the lamination of the cortex. In adult rat brain tissue an
additional analysis of YB-1 in the piriform cortex revealed
an association with layer III. Neuronal YB-1 expression
has previously been reported in the developing brain of
mice as well as of a human 24-week old foetus [26-28].
Our data indicate that neuronal YB-1 expression in spe-
cific brain regions extends to the adult brain and reaches
relevant levels in the brain of adult rats, macaques, and
humans. Predominant localization in the cytoplasm indi-
cates that a large sub-fraction of YB-1 exists in a functional
standby state. These data are in accordance with previous
reports. Studies in primary cultures of hippocampal neu-
rons as well as studies in early postnatal mouse brain tis-
sue have also indicated a primary cytoplasmic localization
[24,25]. Nuclear YB-1 represents the sub-fraction availa-
ble for interference with DNA and RNA which is in the
appropriate localization to regulate the transcriptome and
proteome of the cells. Nuclear translocation proved to act
as a regulatory mechanism in response to a variety of
stresses such as hyperthermia-associated cell stress in
Analysis of neural YB-1 expression in the hippocampal hilus Figure 3
Analysis of neural YB-1 expression in the hippocampal hilus. Data are given as neural density (mean ± SEM). Significant 
differences to controls are indicated by an asterisk. One way analysis of variance indicated that groups differ significantly (p = 
0.0044). (A) Analysis of the hilar density of YB-1 reactive neurons two (n = 2), four (n = 6) or eight hours (n = 7) after status 
epilepticus did not show significant differences to controls (n = 8) (in all cases p > 0.05). In contrast, the neural density of YB-1 
expressing cells was decreased 48 hours (n = 6) after status epilepticus (p = 0.0017). (B) Representative image of the dentate 
hilus (H) of a control rat. (C) Representative image of the dentate hilus (H) of a rat 48 hours after status epilepticus. Note the 
tremendous decrease in YB-1 expressing hilar neurons. (DG = dentate gyrus). Scale bar = 100 μm.BMC Neuroscience 2009, 10:28 http://www.biomedcentral.com/1471-2202/10/28
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human colon carcinoma cells [29] and treatment with the
cytostatic agent paclitaxel in breast cancer patients [30].
YB-1 has been reported to represent one of the key regula-
tors for expression of the multidrug transporter Pgp in
tumor cells [4-10]. Expression levels of the efflux trans-
porter Pgp are of specific interest as Pgp confers cross-
resistance to a variety of cytotoxic agents [11]. Enhanced
efflux of cytostatic drugs decreases concentrations at the
target sites thereby contributing to tumor resistance and
therapeutic failure. Several studies confirmed that high
YB-1 expression levels are linked with tumor aggressive-
ness, failure of chemotherapy, and a poor prognosis in
different tumor types [12-16]. BBB Pgp is discussed as a
contributing factor in drug-refractoriness of various CNS
diseases including epilepsy, brain ischemia, HIV encepha-
lopathy, and psychiatric diseases [17]. Interestingly, evi-
dence exists that Pgp expression can be driven by
pathophysiological mechanisms or by drug therapy [17].
Recently, we reported that a glutamate/NMDA receptor/
cyclooxygenase-2 pathway is involved in the induction of
Pgp in the epileptic brain [22]. However, the downstream
effectors of the cascade still need to be identified. Further-
more translational regulation may also affect expression
levels in the diseased brain. Based on the link between YB-
1 and tumor Pgp, we hypothesized that YB-1 may also reg-
ulate Pgp expression in brain capillary endothelial cells.
However, double-labelling studies with the endothelial
cell marker Glut-1 and with Pgp did not confirm an
expression of YB-1 in endothelial cells. Moreover, no
induction of YB-1 was observed in brain endothelial cells
following prolonged seizure activity in a rat status epilep-
ticus model. Therefore, YB-1 is apparently not involved in
transcriptional and translational regulation in brain capil-
lary endothelial cells neither in the healthy brain nor in
the epileptic brain. Lack of co-localization of YB-1 and the
astrocytic marker GFAP indicates that this conclusion
applies to astrocytes as well. As the majority of astrocytic
endfeet are labelled for GFAP, we can rule out that the YB-
1 expression observed in association with brain microves-
sels is due to an astrocytic expression. The question
remains to be open, whether YB-1 expression in the vicin-
ity of the vascular unit might be related to pericytes.
Detection in pericytes would indicate a role of YB-1 in
transcriptional and translational regulation in these cells
which might affect the overall expression pattern and
activity status. As the role of pericytes was not in the scope
of our interest, we did not further analyze double-label-
ling with pericyte markers.
YB-1 expression was not affected in hippocampal neurons
in the early hours following status epilepticus. This result
argues against a key role of the transcriptional and trans-
lational regulator YB-1 for the complex changes in the
transcriptome and proteome of the hippocampus that
occur following seizure activity [18,19]. However, it needs
to be considered that the functional state of YB-1 might be
additionally affected in all brain regions by changes in its
nuclear translocation, which was not assessed in the status
epilepticus model in the present study. The reduction in
YB-1 labelled cells 48 hours is likely to be associated with
hippocampal cell loss, which is known to be evident at
this time point.
Conclusion
In conclusion, the present study demonstrated neuronal
expression of YB-1 in the hippocampus and parahippoc-
ampal cortex of adult rats, macaques, and humans. In
addition, analysis of rat brain tissue revealed an expres-
sion in the piriform cortex. Double-labelling studies indi-
cated that YB-1 is not expressed in brain capillary
endothelial cells and in astrocytes. Moreover, a co-locali-
zation with Pgp was ruled out arguing against a role of YB-
1 in the regulation of blood-brain barrier Pgp expression.
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